IMMUNOTECH-B (06978) released its annual performance report, with a net loss attributable to shareholders of 231 million yuan, an increase of 23.47% year-on-year.

IMMUNOTECH-B(06978) released its annual performance ending on December 31, 2025. The group achieved other income of 2050.7 million yuan, a decrease of 39.31% year-on-year; research and development expenses were 133 million yuan, a decrease of 13.89% year-on-year; the group's net loss attributable to owners of the company was 2.31 billion yuan, an increase of 23.47% year-on-year; and the loss per share was 0.42 yuan. EAL is a broad-spectrum anti-tumor cell immunotherapy product with over ten years of clinical application in cancer treatment. EAL is a preparation initially derived from T cells from the patient's own peripheral blood, activated, expanded, and cultivated using patented methods. The product's main active component is CD8+ cytotoxic T cells, with CD3 molecules on the cell surface. As of the date of this announcement, the group has completed the enrollment of 430 target subjects for Phase II clinical trials. EAL received conditional NDA application acceptance in March 2025. Subsequently, EAL was included in the priority review and approval list in China. As of the date of this announcement, the conditional NDA application for the group's core candidate product, EAL, is under review by the National Medical Products Administration Drug Evaluation Center.